ETFs Photocure ASA

PHO

NO0010000045

Pharmaceuticals

Market Closed - Oslo Bors 10:45:00 2026-09-21 EDT			5-day change	1st Jan Change
52.80 ^NOK	+2.13%		+2.52%	-26.05%

08-16	Photocure Sees Potential in US FDA's Proposed Reclassification of Cystoscopy Systems	MT
08-14	Photocure ASA Initiates FDA Proposal To Reclassify Blue Light Cystoscopy Systems From Class III To Class II	CI

ETFs positioned on Photocure ASA

Name	YTD change	Weight	AuM
STATE STREET SPDR S&P INTERNATIONAL SMALL CAP ETF - USD	+13.68%	0.02%	918 M€
DIMENSIONAL INTERNATIONAL SMALL CAP ETF - USD	+12.61%	0%	5,871 M€
STATE STREET SPDR PORTFOLIO EUROPE ETF - USD	+5.74%	0%	742 M€
STATE STREET SPDR GLOBAL ALLOCATION ETF - DISTRIBUTING - USD	+8.70%	0%	317 M€
DIMENSIONAL WORLD EQUITY ETF - USD	+14.63%	0%	1,674 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+15.01%	0%	62 M€
DIMENSIONAL INTERNATIONAL SUSTAINABILITY CORE 1 ETF - USD	+8.37%	0%	1,193 M€

Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Companyâ€™s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.

Employees

100

Sector

Pharmaceuticals

Calendar

10-27 Earnings release - Q3 2026

More about the company